Chemotherapy in epithelial ovarian cancer

被引：79

作者：

Pignata, Sandro ^{[1
]}

Cannella, Lucia ^{[1
]}

Leopardo, Davide ^{[1
]}

Pisano, Carmela ^{[1
]}

Bruni, Giovanni Salvatore ^{[1
]}

Facchini, Gaetano ^{[1
]}

机构：

[1] Natl Canc Inst Naples, Dept Urol & Gynecol, Div Med Oncol, I-80131 Naples, Italy

来源：

CANCER LETTERS | 2011年 / 303卷 / 02期

关键词：

Ovarian cancer; Chemotherapy; PEGYLATED LIPOSOMAL DOXORUBICIN; PHASE-III TRIAL; PACLITAXEL-RESISTANT OVARIAN; GYNECOLOGIC-ONCOLOGY-GROUP; INTRAPERITONEAL CISPLATIN; INTERGROUP TRIAL; RANDOMIZED-TRIAL; INTRAVENOUS CHEMOTHERAPY; DOCETAXEL-CARBOPLATIN; 1ST-LINE TREATMENT;

D O I：

10.1016/j.canlet.2011.01.026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Epithelial ovarian cancer is the most common type of ovarian cancer; usually occurs in women older than 50 years, and because 75% of cases are diagnosed at stage III or IV it is associated with a poor prognosis. Treatment of ovarian cancer is based on the integration of surgery and chemotherapy. Chemotherapy plays a major role both in the adjuvant treatment and in the care of patients with advanced disease. Several active drugs have been introduced in the treatment of ovarian cancer in the last decades and novel targets and agents are under evaluation. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

引用

收藏

页码：73 / 83

页数：11

相关论文

共 50 条

[31] Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer [J].

Fujiwara, K ;

Markman, M ;

Morgan, M ;

Coleman, RL .

GYNECOLOGIC ONCOLOGY, 2005, 97 (01) :10-15

[32] Cytologic changes of ovarian epithelial cancer induced by neoadjuvant chemotherapy [J].

Wang, Yiying ;

Wang, Yue ;

Zheng, Wenxin .

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2013, 6 (10) :2121-2128

[33] Role of chemotherapy in the management of epithelial ovarian cancer [J].

Reed, NS ;

Sadozye, AH .

EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (01) :139-147

[34] Chemotherapy in epithelial ovarian cancer; literature review [J].

Alberto Alfonso, Pimentel-Renteria ;

Maria Guadalupe, Cervantes-Sanchez .

GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (04) :161-174

[35] The Significance of Combination Chemotherapy in Epithelial Ovarian Cancer [J].

Kwon, Janice S. ;

McGahan, Colleen ;

Dehaeck, Ulrike ;

Santos, Jennifer ;

Swenerton, Kenneth ;

Carey, Mark S. .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (02) :226-232

[36] Maintenance chemotherapy in the management of epithelial ovarian cancer [J].

Maurie Markman .

Cancer and Metastasis Reviews, 2015, 34 :11-17

[37] Treatment of epithelial ovarian cancer [J].

Kuroki, Lindsay ;

Guntupalli, Saketh R. .

BMJ-BRITISH MEDICAL JOURNAL, 2020, 371

[38] Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer A network meta-analysis [J].

Qu, Chang-Ping ;

Sun, Gui-Xia ;

Yang, Shao-Qin ;

Tian, Jun ;

Si, Jin-Ge ;

Wang, Yi-Feng .

MEDICINE, 2017, 96 (02)

[39] Maintenance Chemotherapy in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer after Second-Line Chemotherapy [J].

Chen, Yen-Fu ;

Hsu, Shih-Tien ;

Hwang, Sheau-Feng ;

Sun, Lou ;

Liu, Chih-Ku ;

Shih, Yu-Hsiang ;

Lu, Ting-Fang ;

Wang, Jun-Sing ;

Lu, Chien-Hsing .

JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)

[40] Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer [J].

Krzystyniak, J. ;

Ceppi, L. ;

Dizon, D. S. ;

Birrer, M. J. .

ANNALS OF ONCOLOGY, 2016, 27 :4-10

← 1 2 3 4 5 →